Scott Kopetz

Academic History

Scott Kopetz, MD, PhD, is a Professor of Gastrointestinal Medical Oncology and the Associate Vice President of Translational Integration at the University of Texas MD Anderson Center, Houston, TX. He earned his medical degree from John Hopkins School of Medicine, Baltimore, MD, before completing a PhD in cancer biology at the University of Texas MD Anderson Center. He is also chair of the National Cancer Institute (NCI) Colon Cancer Task Force and vice chair for Colon Cancer in the NSABP/RTG/GOG (NRG) Cooperative Group.

Prof. Kopetz leads research on colorectal cancer, focusing on the development of novel therapeutic combinations and placing emphasis on personalised treatments targeting specific genetic defects. His findings have enhanced our understanding of the immunobiology of minimal residual disease, tumor evolution and therapy resistance in colorectal cancer.

Speaking on precision medicine in colorectal cancer

Prof. Kopetz leads ground-breaking research in colorectal cancer, focusing on the development of targeted therapies and personalized medicine. His work emphasizes the role of precision medicine and biomarkers to optimize treatment regimens and improve patient outcomes. He is actively involved in several large-scale clinical trials aimed at evaluating novel therapies for advanced colorectal cancer, including the use of immunotherapy and combination therapies. Prof. Kopetz also serves as a principal investigator in the development of next-generation treatment strategies and drug discovery, with a strong emphasis on translating laboratory findings into clinical applications.